We are focused on serving the biopharma/biotech market and strive to be a consultative and proactive oncology CRO partner. Our customized solutions are designed around the individual needs of each of our biopharma clients.
Our people, company culture and can-do attitude, along with our unique combination of oncology and rare disease expertise and technology, differentiate us from our competition.
We seek to be more than simply a vendor, by adding value to the clinical development of our biopharma client’s emergent therapies. We pride ourselves on our commitment to delivering high-quality service.
Our Oncology Proposition:
We excel in delivering trials evaluating the latest advances in investigational therapies. Our team is well versed in a plethora of trial designs including dose escalation both biomarker based and not, blind/double blind, cross over trials and others. Our experience enables our ability to help sponsors develop or deliver a personalized approach to medicine and an increased efficiency in investigational product development.
Defined as enrollment of marker + and – patients with randomized to targeted vs. non-targeted therapy
Defined as enrollment of marker + patients only, with or without randomization
Defined as adaptable enrollment during trial from full population to patients who seem to benefit from product under study
Defined as patients randomize to treatment strategy: based on biomarker status vs. not based on biomarker status (e.g., physician’s choice)
Basket trials, umbrella trials, platform trials, etc
MANY MANY thanks for your ongoing support. You have all been top notch, and we are so thankful to be working with Cmed on this study.
Your willingness to work through the problem and find a solution shows the site we’re working hard to provide them with the best possible solutions. This is great news and makes me feel really good about selecting Cmed as our vendor.
How quickly Cmed collectively got the study up and running with our first SIV and FPI likely to be ahead of the planned date. It has ‘mesmerized the investors’.